Skip to main content

Advertisement

Table 3 Changes in treatment for patients not at target at 6 months by target achievement at 12 months

From: Individualised treatment targets in patients with type-2 diabetes and hypertension

  Target achieved at 12 months (N = 763) Target not achieved at 12 months (N = 2136)
6 months % (Δ from BL) 12 months % (Δ from 6 mo) 6 months % (Δ from BL) 12 months % (Δ from 6 mo)
Metformin 82.3 (− 0.9) 82.3 (–) 82.6 (−0.6) 81.7 (−0.9)
Sulfonylurea 20.8 (+ 0.2) 20.1 (− 0.7) 20.9 (+ 0.3) 20.7 (− 0.2)
Glucosidase inhibitor 1.6 (+ 1.4) 1.3 (− 0.3) 1.0 (− 0.2) 0.9 (− 0.1)
Glinide 3.5 (− 0.6) 3.5 (–) 4.6 (+ 0.5) 5.0 (+ 0.4)
Glitazone 0.7 (+ 0.3) 0.8 (+ 0.1) 0.2 (− 0.2) 0.3 (+ 0.1)
DPP-4 inhibitor 63.0 (− 2.8) 62.3 (− 0.7) 66.7 (+ 0.9) 64.8 (− 1.9)
GLP-1 analogue 6.9 (+ 1.1) 6.6 (− 0.3) 6.1 (+ 0.3) 5.8 (− 0.3)
SGLT-2 inhibitor 1.7 (− 1.0) 2.2 (+ 0.5) 3.9 (+ 1.2) 4.3 (+ 0.4)
Any insulin 21.2 (+ 1.8) 24.6 (+ 3.4) 25.0 (+ 5.6) 29.9 (+ 4.9)
  1. BL baseline, DPP dipeptidyl peptidase, GLP glucagon-like peptide, SGLT sodium-glucose transporter protein